Imunon, Inc. reports developments as a clinical-stage biotechnology company advancing non-viral DNA technologies for immunotherapy and vaccines. Its lead candidate, IMNN-001, is a DNA-based interleukin-12 immunotherapy being developed for localized treatment of newly diagnosed advanced ovarian cancer through the OVATION clinical program.
Company news commonly covers clinical data from OVATION studies, Phase 3 development activity, financial results and business updates, and portfolio work around the TheraPlas platform for cytokine and therapeutic-protein delivery and the PlaCCine platform for viral-antigen delivery. Updates also include capital discipline, organization changes, and presentations of translational or proof-of-concept data.
IMUNON (Nasdaq: IMNN) reported a third-quarter net loss available to common shareholders of $3.813 million while advancing its ovarian cancer program. The loss compared with $3.429 million a year earlier; loss per share narrowed to $0.64 from $1.16. Nine-month operating cash use was unchanged at $10.2 million. September 30 cash and equivalents totaled $4.039 million, alongside $5.039 million in restricted cash.
The company expects Phase 3 OVATION 3 enrollment to finish by the first quarter of 2029. It entered a development agreement with the National Cancer Institute and exchanged $1.2 million of debt plus accrued interest for non-convertible preferred stock. A proposed ThermoDox rights sale offers milestone payments of up to $16.5 million, subject to development milestones; closing depends on VoxelDox raising $2.5 million. A proposed securities offering remains pending.
IMUNON (IMNN) presented new patient-biopsy data linking IMNN-001 to increased anti-tumor immune activity in the Phase 2 OVATION 2 ovarian cancer study. Adding IMNN-001 to standard chemotherapy increased ratios of cancer-fighting T cells to other immune cells in both tumors and surrounding tissue. Chemotherapy also supported inflammatory immune-cell changes and reduced infiltration by myeloid cells.
Previously reported final median overall survival was 45.1 months versus 30.4 months with standard care, a 14.7-month improvement; median progression-free survival improved by three months. The company views the biopsy findings as an explanation for those clinical results. The pivotal Phase 3 OVATION 3 trial is enrolling to confirm safety and survival benefit and will extend the immune-response research.
IMUNON (Nasdaq: IMNN) will hold its third-quarter financial results and business update call on November 12, 2026, at 11:00 a.m. EST. The call will cover the quarter ended September 30, 2026, and development of IMNN-001, its investigational DNA-based interleukin-12 immunotherapy, including Phase 3 progress in newly diagnosed advanced ovarian cancer. A live webcast and a 90-day audio replay will be available.
IMUNON (IMNN) has agreed to sell its rights to ThermoDox to VoxelDox Therapeutics in exchange for equity and potential future payments. Upon completion of VoxelDox’s financing, IMUNON will receive an approximately 4.76% equity interest, with potential aggregate development and sales-based milestone payments of up to $16.5 million and tiered royalties of 3.5% to 6% on net sales of ThermoDox-related products, if approved.
Closing depends on VoxelDox completing a planned $2.5 million financing to support initiation of a Phase 1 glioblastoma trial. IMUNON says the transaction supports its focus on the pivotal Phase 3 OVATION 3 trial of IMNN-001 in frontline advanced ovarian cancer. Future economic value depends on VoxelDox’s financing, development and, if applicable, commercialization success.
IMUNON (Nasdaq: IMNN) announced that President and Chief Executive Officer Stacy Lindborg will participate in two investor conferences in October 2026. At the Maxim Growth Summit, held October 12–14 at the Hard Rock Hotel in New York, she will join an oncology panel on October 14 at 9:00 a.m. ET.
At the ThinkEquity Conference on October 15 at the Mandarin Oriental Hotel in New York, her presentation is scheduled for 1:30 p.m. ET in the Boardroom. IMUNON will also host one-on-one meetings throughout the conferences.
IMUNON (IMNN) exchanged $1.2 million of outstanding debt, plus accrued unpaid interest, for newly designated Series B preferred shares. The exchange reduced outstanding debt by approximately 43% and increased stockholders’ equity.
IMUNON issued 120 preferred shares at a purchase price of $10,000 per share and a stated value of $12,000 per share. The shares are not convertible into common stock; no common stock or warrants were issued. IMUNON designated 200 Series B shares in total and expects the issued shares to be classified as permanent equity. The exchange provided no additional cash proceeds.
IMUNON (IMNN) presented Phase 2 survival results and Phase 3 enrollment progress for IMNN-001 in advanced ovarian cancer on September 24, 2026. In the 112-patient randomized OVATION 2 study, median overall survival was 45.1 months with IMNN-001 plus neoadjuvant and adjuvant chemotherapy versus 30.4 months with standard of care alone. The 14.7-month difference came from a study not powered for overall survival.
OVATION 3 is a randomized trial of approximately 500 patients with overall survival as its primary endpoint and two planned, event-driven interim analyses. Enrollment is averaging about 0.5 patients per site per month, versus a 0.3 planning assumption. IMUNON targets completion of enrollment in the first quarter of 2029.
In a separate, preliminary minimal residual disease study, 4 of 9 assessed patients in the IMNN-001 arm had residual disease, versus 6 of 9 controls. The sample is still too small to evaluate efficacy. OVATION 2 reported no cytokine release syndrome or serious systemic immune-related adverse events.
IMUNON (IMNN) reported that an Independent Data Monitoring Committee recommended continuation of its Phase 2 MRD study of IMNN-001 without modification after reviewing all safety data.
The committee found no new safety signals and confirmed comparable safety between treatment arms, with no cytokine release syndrome, systemic toxicities or serious immune-related adverse events observed to date. The MRD trial in newly diagnosed advanced ovarian cancer has now shown safety and tolerability for IMNN-001 both in combination with bevacizumab and in the maintenance setting. Preliminary July data from patients reaching second-look laparoscopy showed IMNN-001 was associated with a lower MRD-positive rate (44% vs 67%), higher ctDNA clearance (87.5% vs 62.5%), and more patients achieving no evidence of disease (100% vs 56%) versus control. The latest review also identified no new safety concerns in the pivotal Phase 3 OVATION 3 trial.
IMUNON (IMNN) has entered a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI) to advance IMNN-001, its DNA-based IL-12 immunotherapy.
Under the CRADA, NCI’s Cancer Therapy Evaluation Program (CTEP), which assumes regulatory sponsorship, will support further clinical and non-clinical development of IMNN-001 within the NCI Experimental Therapeutics (NExT) Program. NCI investigators will study IMNN-001 in new solid tumor indications and combination regimens, extending work from IMUNON’s ovarian cancer program. IMUNON retains ownership of its background intellectual property and any new IP it solely generates, and it can use collaboration data for IMNN-001 research and development.
The company said this partnership leverages NCI resources and the National Clinical Trials Network to initiate additional trials in a capital-efficient manner while IMUNON continues its pivotal Phase 3 OVATION 3 trial. In a prior Phase 2 study, IMNN-001 was associated with a 14.7‑month increase in median overall survival versus chemotherapy alone (45.1 vs. 30.4 months).
IMUNON (IMNN) will host a 2026 R&D Day in New York City and via live webcast on Wednesday, September 23, 2026, starting at 10:00 a.m. ET, focused on its investigational IL-12 immunotherapy IMNN-001.
The event at Sofitel New York will highlight clinical progress across IMNN-001 programs, including the Phase 3 OVATION 3 trial in advanced ovarian cancer and a Phase 2 minimal residual disease (MRD) study conducted with the Break Through Cancer Foundation. A featured segment will be a conversation with an OVATION 1 trial participant sharing her experience with IMNN-001 and life after the study.
The agenda includes scientific and clinical presentations from IMUNON executives and external gynecologic oncology experts, covering IL-12 delivery via TheraPlas™, translational MRD insights, OVATION 2 overall survival signals informing OVATION 3, and IMUNON’s strategic milestones, catalysts and investment outlook. A live Q&A and networking session will follow.